Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q1 2023 · 10-Q
Revenue$605.84K$605.84K+55.7% vs Q1 2022 Net Income-$856.55K-$856.55KN/M vs Q1 2022 EPS Diluted-$0.56-$0.56N/M vs Q1 2022 Operating Income-$915,175N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
Margins · derivedOperating margin-151.1%+265.3 pt vs Q1 2022
Net margin-141.4%+268.3 pt vs Q1 2022
ended Mar 31, 2023 · filed May 11, 2023 · 41 d after period end